TY - JOUR
T1 - Cutaneous cytomegalovirus (CMV) infection in a patient with metastasized lung cancer
AU - Lee, Chaw Ning
AU - Po-Chao Chiu, Frank
AU - Hsu, Chao Kai
N1 - Publisher Copyright:
© 2021 European Society of Clinical Microbiology and Infectious Diseases
PY - 2021/4
Y1 - 2021/4
N2 - Diagnosing cutaneous cytomegalovirus (CMV) is difficult due to its rarity and diverse manifestations, and early recognition is crucial as it may indicate disseminated disease and a poor prognosis. We examined a 71-year-old Taiwanese male presenting with a 1-week history of progressive, painful papulopustules associated with superficial ulcers and thick yellowish crusts on the scalp. He had been diagnosed with stage IVb lung adenocarcinoma 6 weeks earlier, and the epidermal growth factor receptor inhibitor (EGFRI) erlotinib and radiotherapy had been started to treat brain metastases 1 month before he came to our clinic. Histopathological examination of a scalp lesion and ELISA and PCR testing of blood samples were indicative of disseminated CMV infection. Unfortunately, the patient passed away the day after his scalp biopsy, before the investigations confirmed the infection. We would like to highlight the importance of remaining vigilant for cutaneous CMV in end-stage cancer patients receiving tyrosine kinase inhibitors (TKIs) and recognizing how this potentially life-threatening viral infection can masquerade as a possible side effect of erlotinib.
AB - Diagnosing cutaneous cytomegalovirus (CMV) is difficult due to its rarity and diverse manifestations, and early recognition is crucial as it may indicate disseminated disease and a poor prognosis. We examined a 71-year-old Taiwanese male presenting with a 1-week history of progressive, painful papulopustules associated with superficial ulcers and thick yellowish crusts on the scalp. He had been diagnosed with stage IVb lung adenocarcinoma 6 weeks earlier, and the epidermal growth factor receptor inhibitor (EGFRI) erlotinib and radiotherapy had been started to treat brain metastases 1 month before he came to our clinic. Histopathological examination of a scalp lesion and ELISA and PCR testing of blood samples were indicative of disseminated CMV infection. Unfortunately, the patient passed away the day after his scalp biopsy, before the investigations confirmed the infection. We would like to highlight the importance of remaining vigilant for cutaneous CMV in end-stage cancer patients receiving tyrosine kinase inhibitors (TKIs) and recognizing how this potentially life-threatening viral infection can masquerade as a possible side effect of erlotinib.
UR - http://www.scopus.com/inward/record.url?scp=85101374258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101374258&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2021.01.016
DO - 10.1016/j.cmi.2021.01.016
M3 - Comment/debate
C2 - 33524588
AN - SCOPUS:85101374258
SN - 1198-743X
VL - 27
SP - 565
EP - 567
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 4
ER -